Spartanamicin B
Latest Information Update: 10 Jun 2005
At a glance
- Originator Michigan State University
- Class Antibacterials; Antifungals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 10 Jun 2005 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 06 Jul 1998 No-Development-Reported for Mycoses in USA (Unknown route)
- 29 Aug 1995 Preclinical development for Mycoses in USA (Unknown route)